The estimated Net Worth of Oort Douglas M Van is at least $49.3 Million dollars as of 12 November 2020. Mr. Van owns over 500,000 units of Neogenomics stock worth over $41,146,705 and over the last 11 years he sold NEO stock worth over $4,515,000. In addition, he makes $3,648,730 as Chairman of the Board and Chief Executive Officer at Neogenomics.
Douglas has made over 8 trades of the Neogenomics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 500,000 units of NEO stock worth $3,760,000 on 12 November 2020.
The largest trade he's ever made was exercising 1,000,000 units of Neogenomics stock on 8 March 2016 worth over $800,000. On average, Douglas trades about 167,738 units every 71 days since 2014. As of 12 November 2020 he still owns at least 2,522,790 units of Neogenomics stock.
You can see the complete history of Mr. Van stock trades at the bottom of the page.
Douglas M. VanOort serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of the Company since October 28, 2009. For seven months prior to October 2009, he served as Chairman of the Board of Directors, Executive Chairman and Interim Chief Executive Officer. Prior to joining the Company, Mr. VanOort was a General Partner with a private equity firm, and a Founding Managing Partner of a venture capital firm. From 1982 through 1999, Mr. VanOort served in various positions at Corning Incorporated (“Corning”) and at its spin-off company, Quest Diagnostics, Inc. (“Quest Diagnostics”). During the period from 1995 through 1999, he served as the Senior Vice President Operations for Quest Diagnostics which was then a $1.5 billion newly formed NYSE-traded Company. During the period of 1989 to 1995, he held senior executive positions at Corning Life Sciences, Inc., including Executive Vice President. Corning Life Sciences Inc. had revenues of approximately $2 billion and was spun-off in a public transaction to create both Quest Diagnostics and Covance, Inc. From 1982 to 1989, Mr. VanOort served in various executive positions at Corning, including Director of Mergers & Acquisitions. Mr. VanOort currently serves as the Chair of the American Clinical Laboratory Association where he previously served as a member of the Board. Mr. VanOort is a graduate of Bentley University.
As the Chairman of the Board and Chief Executive Officer of Neogenomics, the total compensation of Douglas VanOort at Neogenomics is $3,648,730. There are no executives at Neogenomics getting paid more.
Douglas VanOort is 64, he's been the Chairman of the Board and Chief Executive Officer of Neogenomics since 2009. There are 3 older and 23 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Oort's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, 33913.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van, and Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: